Skip to content

Author

Mustafa Altınbaş

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Remnant cholesterol inflammatory index for predicting pathological complete response to neoadjuvant therapy in breast cancer: A multicenter external validation study

Background Pathological complete response (pCR) after neoadjuvant therapy (NAT) is associated with long-term outcomes in breast cancer (BC). The remnant cholesterol inflammatory index (RCII) integrates lipid-related and inflammatory components, but its role in pCR prediction remains unclear. Methods This multicenter re...

Galip Can Uyar, Kadriye Başkurt, Ahmet Oruç et al. · 0 citations
Sep 2026

Real-world outcomes of ribociclib treatment in HR-positive/HER2-negative metastatic breast cancer: efficacy, safety, and prognostic factors.

BACKGROUND This study evaluated the real-world efficacy, safety, and prognostic factors associated with progression-free survival (PFS) in patients with HR-positive/HER2-negative metastatic breast cancer treated with ribociclib. RESEARCH DESIGN AND METHODS This retrospective single-center study included 110 patients...

Salih Karatlı, D. Yazılıtaş, Mustafa Altınbaş · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.